These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 9013093)

  • 1. Changes in biliary lipid output after interruption of pravastatin treatment in humans.
    Hillebrant CG; Eriksson M; Nyberg B; Einarsson K
    Eur J Clin Invest; 1996 Dec; 26(12):1160-5. PubMed ID: 9013093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients.
    Hillebrant CG; Axelson M; Björkhem I; Wang FH; Nyberg B; Einarsson C
    Eur J Clin Invest; 1998 Apr; 28(4):324-8. PubMed ID: 9615912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
    Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
    N Engl J Med; 1990 Jul; 323(4):224-8. PubMed ID: 2114543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of plasma low density lipoprotein apheresis on the hepatic secretion of biliary lipids in humans.
    Hillebrant CG; Nyberg B; Einarsson K; Eriksson M
    Gut; 1997 Nov; 41(5):700-4. PubMed ID: 9414982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolaemia.
    Hoogerbrugge-vd Linden N; de Rooy FW; Jansen H; van Blankenstein M
    Gut; 1990 Mar; 31(3):348-50. PubMed ID: 2108908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pravastatin-induced decrease of biliary cholesterol secretion is not directly related to an inhibition of cholesterol synthesis in humans.
    Kallien G; Lange K; Stange EF; Scheibner J
    Hepatology; 1999 Jul; 30(1):14-20. PubMed ID: 10385633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of withdrawal of pravastatin on biliary lipid composition in humans.
    Muraca M; Baggio G; Vilei MT; Martini S; Cianci V; Crepaldi G
    Atherosclerosis; 1996 Jun; 123(1-2):133-7. PubMed ID: 8782844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancement of fatty acid and cholesterol synthesis accompanied by enhanced biliary but not very-low-density lipoprotein lipid secretion following sustained pravastatin blockade of hydroxymethyl glutaryl coenzyme A reductase in rat liver.
    Carrella M; Fong LG; Loguercio C; Del Piano C
    Metabolism; 1999 May; 48(5):618-26. PubMed ID: 10337863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of long-term treatment with low-dose pravastatin on biliary lipid and bile acid composition in patients with nonfamilial hyperlipoproteinemia.
    Tazuma S; Takizawa I; Kunita T; Mizuno T; Watanabe T; Teramen K; Horikawa K; Ochi H; Yamashita Y; Aihara N
    Metabolism; 1995 Nov; 44(11):1410-2. PubMed ID: 7476326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of pravastatin on hepatic cholesterol metabolism].
    Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
    Fortschr Med; 1991 Mar; 109(8):189-94. PubMed ID: 1905265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition.
    Bard JM; Parra HJ; Douste-Blazy P; Fruchart JC
    Metabolism; 1990 Mar; 39(3):269-73. PubMed ID: 2106607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of cholesterol-lowering on plasma membrane lipids and function.
    Lijnen P; Echevaría-Vázquez D; Petrov V
    Methods Find Exp Clin Pharmacol; 1996 Mar; 18(2):123-36. PubMed ID: 8740244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of combined treatment with pravastatin and ursodeoxycholic acid on hepatic cholesterol metabolism.
    Hillebrant CG; Nyberg B; Gustafsson U; Sahlin S; Björkhem I; Rudling M; Einarsson C
    Eur J Clin Invest; 2002 Jul; 32(7):528-34. PubMed ID: 12153554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of the 3-hydroxy, 3-methylglutaryl coenzyme A reductase inhibitor pravastatin on bile composition and nucleation of cholesterol crystals in cholesterol gallstone disease.
    Smit JW; van Erpecum KJ; Renooij W; Stolk MF; Edgar P; Doornewaard H; Vanberge-Henegouwen GP
    Hepatology; 1995 Jun; 21(6):1523-9. PubMed ID: 7768495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute effects of HMG-CoA reductase inhibitors on biliary lipids in patients with interrupted enterohepatic circulation.
    Muraca M; Baggio G; Miconi L; Vilei MT; Martini S; Gabelli C; Belluco C; Lise M; Crepaldi G
    Eur J Clin Invest; 1991 Apr; 21(2):204-8. PubMed ID: 1905632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of pravastatin and ursodeoxycholic acid on cholesterol and bile acid metabolism in patients with cholesterol gallstones.
    Okamoto S; Nakano K; Kosahara K; Kishinaka M; Oda H; Ichimiya H; Chijiiwa K; Kuroki S
    J Gastroenterol; 1994 Feb; 29(1):47-55. PubMed ID: 8199696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of mdr2 gene transcription mediates the biliary transfer of phosphatidylcholine supplied by an increased biosynthesis in the pravastatin-treated rat.
    Carrella M; Feldman D; Cogoi S; Csillaghy A; Weinhold PA
    Hepatology; 1999 Jun; 29(6):1825-32. PubMed ID: 10347126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effects of two HMG-CoA reductase inhibitors (lovastatin and pravastatin) on serum lipids and lipoproteins.
    Richter WO; Jacob BG; Schwandt P
    Int J Tissue React; 1991; 13(2):107-10. PubMed ID: 1955291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on hepatic cholesterol 7 alpha-hydroxylase, acyl-coenzyme A: cholesterol acyltransferase, and bile lipid secretion in the hamster with intact enterohepatic circulation.
    Hayashi K; Noshiro M; Kurushima H; Kuga Y; Nomura S; Ohkura Y; Ohtani H; Kurokawa J; Tanaka K; Yasunobu Y
    Atherosclerosis; 1994 Dec; 111(2):183-9. PubMed ID: 7718020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.